08:43 AM EDT, 07/10/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) said Thursday its partner Pelthos Therapeutics ( PTHS ) has commercially launched Zelsuvmi, an at-home treatment for a skin infection called molluscum contagiosum, which has been approved by the US Food and Drug Administration.

Under the terms of the license agreement with Pelthos, Ligand said it is entitled to a 13% royalty on Zelsuvmi global sales and up to an additional $5 million in commercial sales milestones.

Ligand, which owns 56% of Pelthos after the close of its merger with Channel Therapeutics, said it has earned a $5 million milestone payment from Pelthos for the launch.